Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.
Fair value with mediocre balance sheet.
Share Price & News
How has Mallinckrodt's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MCD's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MCD underperformed the German Pharmaceuticals industry which returned 18.7% over the past year.
Return vs Market: MCD underperformed the German Market which returned -2.6% over the past year.
Price Volatility Vs. Market
How volatile is Mallinckrodt's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Mallinckrodt undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MCD (€2.97) is trading below our estimate of fair value (€20.25)
Significantly Below Fair Value: MCD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MCD is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: MCD is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MCD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MCD is good value based on its PB Ratio (0.1x) compared to the XE Pharmaceuticals industry average (3.1x).
How is Mallinckrodt forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MCD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MCD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MCD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MCD's revenue is expected to decline over the next 3 years (-4.3% per year).
High Growth Revenue: MCD's revenue is forecast to decline over the next 3 years (-4.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MCD's Return on Equity is forecast to be high in 3 years time (22.1%)
How has Mallinckrodt performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MCD is currently unprofitable.
Growing Profit Margin: MCD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MCD is unprofitable, and losses have increased over the past 5 years at a rate of -44.4% per year.
Accelerating Growth: Unable to compare MCD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MCD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).
Return on Equity
High ROE: MCD has a negative Return on Equity (-64.31%), as it is currently unprofitable.
How is Mallinckrodt's financial position?
Financial Position Analysis
Short Term Liabilities: MCD's short term assets ($1.9B) exceed its short term liabilities ($1.3B).
Long Term Liabilities: MCD's short term assets ($1.9B) do not cover its long term liabilities ($7.0B).
Debt to Equity History and Analysis
Debt Level: MCD's debt to equity ratio (278.7%) is considered high.
Reducing Debt: MCD's debt to equity ratio has increased from 77.4% to 278.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable MCD has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: MCD is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 5.5% per year.
What is Mallinckrodt's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MCD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MCD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MCD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MCD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MCD's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Trudeau (58yo)
Mr. Mark Christopher Trudeau has been the Chief Executive Officer and President at Mallinckrodt Public Ltd Company since June 2013. Mr. Trudeau was joined Covidien plc as Senior Vice President and Presiden ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD14.61M) is above average for companies of similar size in the German market ($USD766.05K).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
|Executive VP & CFO||1.17yrs||US$3.13m||0.0089% $23.1k|
|Executive VP & Chief Scientific Officer||no data||US$4.62m||0.041% $106.8k|
|Executive VP & Chief Legal Officer||2.25yrs||US$3.96m||0.056% $144.3k|
|Executive VP & Chief Commercial Officer||no data||US$4.41m||0.057% $146.8k|
|Vice President of Investor Relations & Investor Relations Officer||2.33yrs||no data||no data|
|Senior VP & Chief Compliance Officer||0.67yr||no data||no data|
|Senior VP & Chief Communications Officer||no data||no data||no data|
|Executive VP & Chief Human Resources Officer||no data||US$2.15m||0.063% $161.2k|
|Senior VP & Chief Medical Officer||no data||no data||no data|
Experienced Management: MCD's management team is considered experienced (2.3 years average tenure).
|Independent Non-Executive Chairman||2yrs||US$567.00k||0.061% $157.9k|
|Independent Director||6.92yrs||US$404.40k||0.045% $116.8k|
|Independent Director||6.92yrs||US$420.00k||0.040% $103.9k|
|Independent Director||6.92yrs||US$416.90k||0.050% $128.3k|
|Independent Director||2.67yrs||US$415.00k||0.031% $79.8k|
|Independent Director||6.92yrs||US$415.00k||0.056% $143.7k|
|Independent Director||2yrs||US$400.00k||0.024% $62.0k|
|Independent Director||2yrs||US$400.00k||0.025% $64.3k|
|Member of Scientific Advisory Council||1.92yrs||no data||no data|
Experienced Board: MCD's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mallinckrodt plc's company bio, employee growth, exchange listings and data sources
- Name: Mallinckrodt plc
- Ticker: MCD
- Exchange: DB
- Founded: 1867
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$282.925m
- Listing Market Cap: US$257.547m
- Shares outstanding: 84.46m
- Website: https://www.mallinckrodt.com
Number of Employees
- Mallinckrodt plc
- 3 Lotus Park
- The Causeway
- TW18 3AG
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MNK||NYSE (New York Stock Exchange)||Yes||New Ordinary Shares||US||USD||Jun 2013|
|MCD||DB (Deutsche Boerse AG)||Yes||New Ordinary Shares||DE||EUR||Jun 2013|
|MCD||XTRA (XETRA Trading Platform)||Yes||New Ordinary Shares||DE||EUR||Jun 2013|
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/27 04:18|
|End of Day Share Price||2020/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.